Rheumatoid Arthritis Drugs Market Size to Grow US$ 70 Billion By 2030

According to the report, the global rheumatoid arthritis drugs market size is projected to garner US$ 70 billion by 2030, registering a CAGR of 1.72% from 2022 to 2030. The report contains 150+ pages with detailed analysis.

The increased prevalence of rheumatoid arthritis is one of the major reasons driving the global rheumatoid arthritis medications market. According to a study published in November 2020, the global prevalence of rheumatoid arthritis was anticipated to be 0.46% based on a systematic review. As a result, more rheumatoid arthritis treatments will be prescribed, propelling the market for these medications forward. Increased launches of novel biologics and rising generic medicine penetration are projected to boost the global rheumatoid arthritis pharmaceuticals market significantly.

Growing patient knowledge of rheumatoid arthritis problems is another factor driving the global rheumatoid arthritis medications market. The worldwide rheumatoid arthritis medications industry is also being propelled forward by government authorities’ increasing efforts.

Download the Sample Pages of this Report for Better Understanding (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1755

Report Scope of the Rheumatoid Arthritis Drugs Market

Report Highlights

• On the basis of molecule type, biologics segment holds the largest market share in the global rheumatoid arthritis drugs market. Biological pharmaceuticals are expected to account for the majority of revenue in established nations over the predicted period. Due to the high cost of biologics, these treatments face significant competition from biosimilars and generic pharmaceuticals in emerging nations.
• On the basis of sales channel, prescription drugs segment holds the largest market share in the global rheumatoid arthritis drugs market. Overuse of rheumatoid arthritis drugs for a long time can develop to treatment resistance, thus patients with this disorder should see a rheumatologist and follow their recommendations.

Regional Snapshot

North America region is the fastest growing region in the rheumatoid arthritis drugs market. The U.S. hold the highest market share in the North America rheumatoid arthritis drugs market. According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. In addition, the Canadian government estimates that 374,000 Canadians aged 16 and up suffer from rheumatoid arthritis. Because of the disease’s extensive prevalence, more medicines will be taken, leading in a growth in the rheumatoid arthritis drugs market in North America.

Asia-Pacific is the largest segment for rheumatoid arthritis drugs market in terms of region.China and Indiaare dominating the rheumatoid arthritis drugs market in the Asia-Pacific region. Rising knowledge of disease remission therapy, high public and private healthcare expenditure, and rising rheumatoid arthritis incidences are all driving the Asia-Pacific rheumatoid arthritis medications market. Furthermore, easy access to high-quality healthcare, a solid clinical product range, favorable reimbursement standards, and the approval of novel medications are projected to boost revenue growth in the Asia-Pacific area.

Market Dynamics

Drivers:  Surge in prevalence of rheumatoid arthritis

The ageing population is mainly accountable for the rising incidences of rheumatoid arthritis. Furthermore, some evidence suggests that smokers are more likely to develop rheumatoid arthritis. The rise in the senior population, higher usage of traditional disease modifying antirheumatic drugs, and government measures to disseminate awareness of rheumatoid arthritis symptoms are the primary drivers driving the growth of global rheumatoid arthritis drugs market.

Restraints: Lack of awareness and high cost of rheumatoid arthritis drugs

The key limits of the global rheumatoid arthritis drugs market are expected to be medication related undesirable effects and high pricing of biological disease modifying antirheumatic drugs therapy. The most significant market limitation is the high cost of pharmaceuticals, as therapy is far more expensive and the average person cannot afford it in cases where there is no cure for the disease. The global rheumatoid arthritis drugs market is projected to face challenges due to a lack of awareness, particularly in emerging nations.

Opportunities: Growing advancements in biologics

Theadvances in sophisticated biologics, increased purchasing power, increased healthcare expenditure, and worldwide access to high quality medications for middle and poor class families are all contributing factors. On the other hand, due to enhanced treatment regarding early treatment and screening of rheumatoid arthritis, the global rheumatoid arthritis drugs market is predicted to rise quickly and shift the market outlook. As a result, growing advancements in biologics is creating lucrative opportunities for the growth of global rheumatoid arthritis drugs market.

Challenges: Lack of resources in underdeveloped nations

The underdeveloped countries do not have enough resources for the development of rheumatoid arthritis drugs. As a result, lack of resources in underdeveloped nations is a major challenge for the expansion of worldwide rheumatoid arthritis drugs market.

Recent Developments

• Xbrane Biopharma AB and Biogen Inc. signed a commercialization and license agreement in February 2022 to develop, produce, and market Xcimzane, a preclinical monoclonal antibody that is suggested biosimilar of CIMZIA for the treatment of rheumatoid arthritis.
• The Food & Drug Administration approved Pfizer’s biosimilar, abriladaTM, for a number of inflammatory disorders, particularly rheumatoid arthritis, in November 2019.
• ROS Therapeutics, is developing a targeted methotrexate prodrug to reduce toxicity in the treatment of patients with rheumatoid arthritis.
• In 2020, Bayer AG announced that it would invest around $59 million in the establishment of new manufacturing and supply facility at Beijing Economic Technological Development.

Top Key Players includes in the rheumatoid arthritis drugs market:

• AbbVie
• Boehringer Ingelheim GmbH
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Pfizer, Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• UCB S.A.
• Johnson & Johnson Services, Inc.
• Amgen, Inc.

Segments Covered in the Report

By Molecule

• Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
• Biopharmaceuticals
  • Biologics
    • TNF-α antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • anti-IL6 biologics
  • Biosimilars
    • CD20 antigen
    • TNF-α antagonists

By Sales Channel

• Prescription
• Over-the-Counter (OTC)

 By Route of Administration

• Oral
• Parenteral

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Malaysia
  • Philippines
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of the Middle East & Africa

Why should you invest in this report?

If you are aiming to enter the global rheumatoid arthritis drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for rheumatoid arthritis drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1755

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: [email protected]

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook